Consumer Portfolio Service is a finance company. The company's primary business is to purchase and service retail automobile contracts originated primarily by franchised automobile dealers and select independent dealers in the United States in the sale of new and used automobiles, light trucks and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers who have limited credit histories or past credit problems, who the company refers to as sub-prime customers. The company provides eight different financing programs: Bravo, First Time Buyer, Mercury / Delta, Standard, Alpha, Alpha Plus, Super Alpha and Preferred.

Cryoport provides temperature controlled logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and cold chain logistics knowhow. The company's services are utilized for temperature-controlled shipping and storage and information in the life sciences industry, which includes personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision controlled temperatures.

Littelfuse is a manufacturer of technologies in circuit protection, power control and sensing. The company has three segments: Electronics, which provides fuses and fuse accessories, positive temperature coefficient resettable fuses, polymer electrostatic discharge suppressors, varistors, and gas discharge tubes; Automotive, which consists of circuit protection, power control and sensing technologies for original equipment manufacturers, Tier-I suppliers and parts distributors in the passenger car, agricultural, construction and other commercial vehicle industries; and Industrial, which includes power fuses, protection relays and controls and other circuit protection products.

Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The company has product candidates in clinical and preclinical development to treat post-surgical ocular pain and inflammation, allergic conjunctivitis, dry eye disease, among other conditions. The company's drug application, DEXTENZA? (dexamethasone ophthalmic insert) 0.4mg is for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The company is also assessing the potential use of its hydrogel platform technology in other areas of the body.

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. The company's clinical pipeline consists of its main program, cirmtuzumab, a humanized monoclonal antibody that binds to Receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The company is also developing a chimeric antigen receptor T-cells product candidate that targets ROR1.

Performant Financial provides echnology-enabled audit, recovery, outsource customer services, and related analytics services. The company's services help identify improper payments, and in some markets, restructure and recover delinquent or defaulted assets and improper payments. The company generally provides its services on an outsourced basis, where the company handles various aspects of its clients' recovery processes. The company uses its technology-enabled services platform to provide recovery and analytics services in a range of markets for the identification and recovery of student loans, improper healthcare payments and delinquent state and federal tax and federal treasury receivables.

Vaccinex is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. The company is engaged in the field of semaphorin 4D (SEMA4D) biology, targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. The company is utilizing its SEMA4D antibody platform to develop its primary product candidate, pepinemab (VX15/2503), an antibody that utilizes mechanisms of action. The company is focused on the development of pepinemab for the treatment of non-small cell lung cancer, Huntington's disease, and Alzheimer's disease.

Western Alliance is a bank holding company. Through its subsidiaries, the company provides a variety of financial services to customers, including commercial real estate loans, construction and land development loans, commercial loans, and consumer loans. The company provides deposit products, including checking accounts, savings accounts, money market accounts, and other types of deposit accounts, including fixed-rate, fixed maturity certificates of deposit. In addition to commercial banking activities, the company provides other financial services to its customers, including: internet banking, wire transfers, electronic bill payment and presentment, lock box services, courier, and cash management services.